Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
IMImmunome, Inc. logo

Immunome, Inc. (IMNM)

NASDAQ · Currency in USD
$17.99 ▼ -0.27 (-1.48%)
At close: Oct 23, 4:00 PM ET. Market closed.
$17.99 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$18.26
Open
$18.13
Day's Range
$17.65 – $18.25
52 Week Range
$14.64 – $30.06
Volume
1,353,697
Avg. Volume
1,382,270
Market Cap
$2.12B
Beta (5Y Monthly)
2.13
PE Ratio (TTM)
--
EPS (TTM)
-$2.25
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$33.00

Profile: Immunome, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
247
CEO
Clay Siegall

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.61 · Revenue est. $153.85K
DateEst.Actual
Aug 11, 2026-$0.51-$0.65Miss
May 12, 2026-$0.60-$0.48Beat
Mar 3, 2026-$0.59-$0.75Miss
Nov 6, 2025-$0.57-$0.65Miss
Aug 6, 2025-$0.52-$0.50Beat
May 12, 2025-$0.66-$0.52Beat

Analyst view

Consensus price target
$33.00 ▲ +83.4%
Range $24.00 – $37.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on IMNM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.